Pathology of Gynecological Cancer: The Current Landscape of Diagnosis and Precision Medicine

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gynecologic Oncology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 406

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
Interests: breast cancer; gynecologic cancers; breast pathology; gynecologic pathology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, University Health Network/Sinai Health System, University of Toronto, Toronto, ON M5G 2M9, Canada
Interests: gynecologic cancers; trophoblastic disease; minimally invasive surgery; quality improvement

Special Issue Information

Dear Colleagues,

The fifth edition of the World Health Organization (WHO) Classification of Female Genital Tumors was published in 2020. Clinically significant changes have been made in the pathologic classification of vulvar, cervical and uterine neoplasms, including etiology-based classification of vulvar squamous intraepithelial lesions and squamous cell carcinomas, cervical squamous and glandular lesions, novel histologic subtypes and molecular classification of endometrial carcinoma, novel subtypes of uterine sarcomas and the addition of a fumarate-hydratase-deficient leiomyoma. Although the classification of ovarian and fallopian tube neoplasms has not been significantly changed from the prior edition, important refinements have been achieved, including serous and non-serous epithelial tumors, and sex cord–stromal tumors.

In this Special Issue, we welcome original research articles and reviews that provide critical assessment or further insight into any of the aforementioned gynecologic cancer subtypes and implications for clinical management. Research areas may include, but are not limited to, histologic features and issues in the diagnosis and/or differential diagnosis of challenging entities, ancillary studies, prognostic/predictive biomarkers and the current role of pathologic assessment in precision medicine.

We look forward to receiving your contributions.

Dr. Gulisa Turashvili
Dr. Genevieve Bouchard-Fortier
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • endometrial carcinoma
  • uterine mesenchymal tumors
  • cervical cancer
  • vulvar cancer

Published Papers

This special issue is now open for submission.
Back to TopTop